Taxolab offers outsourced GLP‑compliant toxicology and analytical chemistry services for pharmaceutical and biotechnology companies, including custom assay development, high‑throughput screening, and high‑resolution LC‑MS/MS, GC‑MS, and UHPLC analyses. Results are delivered through a secure, cloud‑based portal with real‑time audit trails and regulatory‑ready reporting to streamline preclinical decision‑making and submission filings.
Funding
$135.5K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pharmaceutical and biotechnology programs require accurate toxicology and analytical chemistry data to satisfy regulatory requirements and inform preclinical decision‑making, yet many organizations lack dedicated in‑house expertise, face long assay development cycles, and encounter high costs for compliant testing.
Solution
Taxolab delivers outsourced laboratory services that cover the full spectrum of toxicology and analytical chemistry testing for drug development programs. The company partners with pharma and biotech clients to design, develop, and validate custom assays that meet GLP and ICH standards, accelerating the generation of high‑quality data. Results are provided through a secure, cloud‑based portal with full audit trails, enabling seamless integration into regulatory submissions and internal review processes. By leveraging advanced instrumentation and experienced scientists, Taxolab reduces turnaround time and operational overhead for its customers while maintaining data integrity required for FDA, EMA, and other agency filings.
Target Audience
Primary customers are pharmaceutical and biotechnology companies conducting drug discovery, preclinical development, and regulatory filing activities that require outsourced toxicology and analytical chemistry expertise.
Features
- GLP‑compliant in‑vitro and in‑vivo toxicology assays, including cytotoxicity, genotoxicity, and organ‑specific toxicity panels
- High‑resolution LC‑MS/MS, GC‑MS, and UHPLC platforms for quantitative bioanalysis and impurity profiling
- Custom method development and validation services aligned with ICH Q2(R1) guidelines
- High‑throughput screening capability for early‑stage compound triage
- Secure client portal delivering raw data, validated reports, and audit‑ready documentation in real time
- Integrated sample logistics with temperature‑controlled shipping and chain‑of‑custody tracking
- Stability testing and metabolite identification workflows supporting IND and NDA submissions
- Dedicated regulatory reporting packages formatted for FDA eCTD, EMA, and other submission portals